Cargando…

Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality

SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodidela, Sunitha, Godse, Sandip, Kumar, Asit, Nguyen, Xuyen H., Cernasev, Alina, Zhou, Lina, Singh, Ajay Kumar, Bhat, Hari K., Kumar, Santosh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869385/
https://www.ncbi.nlm.nih.gov/pubmed/35205044
http://dx.doi.org/10.3390/biology11020177
_version_ 1784656485183127552
author Kodidela, Sunitha
Godse, Sandip
Kumar, Asit
Nguyen, Xuyen H.
Cernasev, Alina
Zhou, Lina
Singh, Ajay Kumar
Bhat, Hari K.
Kumar, Santosh
author_facet Kodidela, Sunitha
Godse, Sandip
Kumar, Asit
Nguyen, Xuyen H.
Cernasev, Alina
Zhou, Lina
Singh, Ajay Kumar
Bhat, Hari K.
Kumar, Santosh
author_sort Kodidela, Sunitha
collection PubMed
description SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. Moreover, since HIV patients are at a higher risk of contracting COVID-19, their neurological problems can be exacerbated by COVID-19. The use of dietary supplements together with available treatment options has been shown to reduce the severity of infections. However, these treatments are not chemically compatible with the body’s blood–brain barrier defense mechanism. Therefore, a viable delivery method is needed to deliver drugs and nutraceuticals to the brain in HIV and COVID-19 comorbid patients. ABSTRACT: People living with HIV/AIDS (PLWHA) are at an increased risk of severe and critical COVID-19 infection. There is a steady increase in neurological complications associated with COVID-19 infection, exacerbating HIV-associated neurocognitive disorders (HAND) in PLWHA. Nutraceuticals, such as phytochemicals from medicinal plants and dietary supplements, have been used as adjunct therapies for many disease conditions, including viral infections. Appropriate use of these adjunct therapies with antiviral proprieties may be beneficial in treating and/or prophylaxis of neurological complications associated with these co-infections. However, most of these nutraceuticals have poor bioavailability and cannot cross the blood–brain barrier (BBB). To overcome this challenge, extracellular vesicles (EVs), biological nanovesicles, can be used. Due to their intrinsic features of biocompatibility, stability, and their ability to cross BBB, as well as inherent homing capabilities, EVs hold immense promise for therapeutic drug delivery to the brain. Therefore, in this review, we summarize the potential role of different nutraceuticals in reducing HIV- and COVID-19-associated neurological complications and the use of EVs as nutraceutical/drug delivery vehicles to treat HIV, COVID-19, and other brain disorders.
format Online
Article
Text
id pubmed-8869385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88693852022-02-25 Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality Kodidela, Sunitha Godse, Sandip Kumar, Asit Nguyen, Xuyen H. Cernasev, Alina Zhou, Lina Singh, Ajay Kumar Bhat, Hari K. Kumar, Santosh Biology (Basel) Review SIMPLE SUMMARY: In this review, we discuss the potential use of extracellular vesicles (EVs) to deliver dietary supplements to the brain to reduce brain complications associated with HIV, COVID-19, and other brain disorders. Brain-related complications affect people with HIV and COVID-19 alike. Moreover, since HIV patients are at a higher risk of contracting COVID-19, their neurological problems can be exacerbated by COVID-19. The use of dietary supplements together with available treatment options has been shown to reduce the severity of infections. However, these treatments are not chemically compatible with the body’s blood–brain barrier defense mechanism. Therefore, a viable delivery method is needed to deliver drugs and nutraceuticals to the brain in HIV and COVID-19 comorbid patients. ABSTRACT: People living with HIV/AIDS (PLWHA) are at an increased risk of severe and critical COVID-19 infection. There is a steady increase in neurological complications associated with COVID-19 infection, exacerbating HIV-associated neurocognitive disorders (HAND) in PLWHA. Nutraceuticals, such as phytochemicals from medicinal plants and dietary supplements, have been used as adjunct therapies for many disease conditions, including viral infections. Appropriate use of these adjunct therapies with antiviral proprieties may be beneficial in treating and/or prophylaxis of neurological complications associated with these co-infections. However, most of these nutraceuticals have poor bioavailability and cannot cross the blood–brain barrier (BBB). To overcome this challenge, extracellular vesicles (EVs), biological nanovesicles, can be used. Due to their intrinsic features of biocompatibility, stability, and their ability to cross BBB, as well as inherent homing capabilities, EVs hold immense promise for therapeutic drug delivery to the brain. Therefore, in this review, we summarize the potential role of different nutraceuticals in reducing HIV- and COVID-19-associated neurological complications and the use of EVs as nutraceutical/drug delivery vehicles to treat HIV, COVID-19, and other brain disorders. MDPI 2022-01-23 /pmc/articles/PMC8869385/ /pubmed/35205044 http://dx.doi.org/10.3390/biology11020177 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kodidela, Sunitha
Godse, Sandip
Kumar, Asit
Nguyen, Xuyen H.
Cernasev, Alina
Zhou, Lina
Singh, Ajay Kumar
Bhat, Hari K.
Kumar, Santosh
Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title_full Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title_fullStr Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title_full_unstemmed Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title_short Nutraceuticals in HIV and COVID-19-Related Neurological Complications: Opportunity to Use Extracellular Vesicles as Drug Delivery Modality
title_sort nutraceuticals in hiv and covid-19-related neurological complications: opportunity to use extracellular vesicles as drug delivery modality
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869385/
https://www.ncbi.nlm.nih.gov/pubmed/35205044
http://dx.doi.org/10.3390/biology11020177
work_keys_str_mv AT kodidelasunitha nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT godsesandip nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT kumarasit nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT nguyenxuyenh nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT cernasevalina nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT zhoulina nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT singhajaykumar nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT bhatharik nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality
AT kumarsantosh nutraceuticalsinhivandcovid19relatedneurologicalcomplicationsopportunitytouseextracellularvesiclesasdrugdeliverymodality